Biological Sample Collection Kits Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Biological Sample Collection Kits Market is projected to expand from USD 8.49 Billion in 2025 to USD 12.86 Billion by 2031, registering a CAGR of 7.17%. These kits consist of comprehensive assemblies of instruments and preservation reagents designed to collect, stabilize, and transport specimens like blood, saliva, and tissue for diagnostic and research purposes. Market growth is primarily fueled by the increasing global prevalence of chronic and infectious diseases, which require extensive clinical testing and continuous surveillance. Furthermore, the rapid development of biobanking infrastructure and a rising preference for remote patient monitoring have bolstered demand for efficient, user-friendly collection solutions that support decentralized testing models.

Highlighting the scale of specimen processing needs, MedTech Europe estimated the European medical technology market at approximately €170 billion in 2024, with in vitro diagnostics standing out as the largest sector. Despite this strong demand, market expansion faces a significant hurdle due to the high costs and complexities associated with maintaining cold chain logistics. Temperature fluctuations during transit pose a serious risk to sample integrity and diagnostic accuracy, making the requirement for strict temperature control a limiting factor for broader market reach.

Market Drivers

The increasing global prevalence of infectious diseases and chronic conditions acts as a major driver for the biological sample collection kits market, necessitating frequent diagnostic screening and ongoing disease management. As long-term health issues become more common, healthcare systems depend on effective specimen collection tools for patient care and early detection. For example, the Centers for Disease Control and Prevention reported in April 2025 that 76.4% of US adults had at least one chronic condition in 2023, underscoring the vast population needing regular diagnostics. This burden has led to strong financial backing for research; the National Cancer Institute's budget for fiscal year 2025 was maintained at $7.22 billion as of October 2025, ensuring continued demand for supplies used in clinical trials and preventive screening.

Concurrently, the industry is being reshaped by the rapid growth of home-based and direct-to-consumer testing, which decentralizes the diagnostic process. Patients are increasingly choosing minimally invasive, self-administered collection methods that provide privacy and convenience, reducing the need for traditional phlebotomy centers. This shift is highlighted by the success of digital health providers specializing in remote logistics; Business & Finance reported in March 2025 that LetsGetChecked achieved a turnover of $500 million in 2024, reflecting surging consumer adoption. This trend pushes manufacturers to develop user-friendly kits that maintain sample stability during standard mail transport, extending market reach beyond traditional clinical settings.

Market Challenges

The significant expense and complexity involved in maintaining cold chain logistics represent a major obstacle to the growth of the biological sample collection kits market. Ensuring sample integrity demands an unbroken, temperature-controlled supply chain from collection to the laboratory, requiring costly specialized packaging, refrigerated transport, and continuous monitoring. This financial requirement raises the overall cost of diagnostic testing, limiting the accessibility of these kits in cost-sensitive markets or regions with inadequate infrastructure. Consequently, reliance on such resource-intensive logistics hinders the scalability of decentralized testing, as healthcare providers find it difficult to justify the high operational costs needed to prevent specimen degradation.

The logistical rigidity necessary for this market is underscored by the strict standards applied to global transport hubs. In 2024, the International Air Transport Association noted that over 500 stations globally were certified under its specialized pharmaceutical logistics validation program. This need for a vast, certified network highlights the operational challenges facing the industry, as samples must traverse these highly regulated nodes to ensure viability. Any gap or deviation in this specialized infrastructure risks temperature excursions, resulting in sample invalidation and financial losses that directly impede broader market adoption.

Market Trends

The move toward sustainable and biodegradable materials is fundamentally transforming manufacturing and logistics strategies within the market. Driven by tighter environmental regulations and corporate net-zero targets, manufacturers are increasingly replacing single-use plastics with bio-based polymers and adopting ambient shipping solutions to reduce reliance on cold chains. This shift is supported by the laboratory sustainability movement, which encourages eco-friendly procurement to address the environmental impact of diagnostics. According to the Royal Society of Chemistry in September 2024, global laboratories generate an estimated 5.5 million metric tons of plastic waste annually, a figure that is spurring an industry-wide push for recyclable and waste-reducing specimen transport designs.

At the same time, the rapid uptake of liquid biopsy and non-invasive sampling methods is driving demand for specialized blood collection devices tailored to preserve cell-free DNA (cfDNA). Unlike standard venipuncture tools, these advanced kits utilize proprietary preservatives to stabilize circulating tumor DNA at room temperature, preventing genomic degradation and offering an alternative to invasive tissue biopsies in oncology. This trend is demonstrated by the rising volume of blood-based genomic tests; Natera, Inc. reported in November 2024 that it performed approximately 137,100 oncology tests in the third quarter alone, marking a 54.4% year-over-year increase and indicating massive clinical adoption of these non-invasive tools.

Key Players Profiled in the Biological Sample Collection Kits Market

• Thermo Fisher Scientific, Inc.
• QIAGEN NV
• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories Inc.
• Becton, Dickinson and Company
• Laboratory Corporation of America Holdings
• Seegene Inc.
• Medline Industries, Inc.
• Altona Diagnostics GmbH
• CTK Biotech, Inc.

Report Scope

In this report, the Global Biological Sample Collection Kits Market has been segmented into the following categories:

Biological Sample Collection Kits Market, by Product:

• Swabs
• Viral Transport Media
• Blood Collection Kits

Biological Sample Collection Kits Market, by Application:

• Diagnostics
• Research

Biological Sample Collection Kits Market, by End-Use:

• Hospitals and Clinics
• Diagnostic Centers
• Others

Biological Sample Collection Kits Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Biological Sample Collection Kits Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.